Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
Make a matched gift and support Jewish journalism. DONATE NOW
Fast Forward

BDS founder: An Israel-invented coronavirus vaccine would be ok for boycotters to use

JERUSALEM (JTA) — The founder of the Boycott, Divestment and Sanctions movement against Israel said that if Israel invents a vaccine for the coronavirus those who reject normalization with Israel by boycotting it can still be given the vaccine.

Omar Barghouti made the comments in a Facebook live Arabic-language webinar Sunday titled “BDS and Anti-normalization: The most important strategies to fight against the deal of the century, even in the time of COVID-19.”

Barghouti said that Israel should not be allowed to use the coronavirus crisis to maintain relations with the Palestinian Authority and with other Arab states.

He also said, according to the Jerusalem Post: “if you use medical equipment from Israel — it’s not a problem. Cooperating with Israel against the virus – to begin with, we do not consider it normalization.”

The same is true of other medical breakthroughs, he said.  “If Israel finds a cure for cancer, for example, or any other virus, then there is no problem in cooperating with Israel to save millions of lives,” he said.

He pointed out, the Jerusalem Post reported, that “up until now, we have not been in a situation where we need Israel urgently and no one else can save us but Israel. If that will happen, saving lives is more important than anything else.”

The description of the webinar in the Facebook post accused Israel of exploiting Palestinian workers in the country by not offering them protection against the virus, and accused Israel of “intensifying the looting of the land and arrests, oppression and killing, while normalization continues with the Arab official system.”

The post BDS founder: an Israel-invented coronavirus vaccine would be ok for boycotters to use appeared first on Jewish Telegraphic Agency.

This is a moment of great uncertainty. Here’s what you can do about it.

We hope you appreciated this article. Before you go, we’d like to ask you to please support the Forward’s independent Jewish news. All donations are still being matched by the Forward Board - up to $100,000 until April 24.

This is a moment of great uncertainty for the news media, for the Jewish people, and for our sacred democracy. It is a time of confusion and declining trust in public institutions. An era in which we need humans to report facts, conduct investigations that hold power to account, tell stories that matter and share honest discourse on all that divides us.

With no paywall or subscriptions, the Forward is entirely supported by readers like you. Every dollar you give is invested in the future of the Forward — and telling the American Jewish story fully and fairly.

The Forward doesn’t rely on funding from institutions like governments or your local Jewish federation. There are thousands of readers like you who give us $18 or $36 or $100 each month or year.

Support our mission to tell the Jewish story fully and fairly.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines.
You must comply with the following:

  • Credit the Forward
  • Retain our pixel
  • Preserve our canonical link in Google search
  • Add a noindex tag in Google search

See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.